Corcept Therapeutics Presents ROSELLA Study Data on Relacorilant in Older Ovarian Cancer Patients
The company disclosed findings on its selective cortisol modulator combined with nab-paclitaxel in patients aged 65 and older with platinum-resistant ovarian cancer.
Study Presentation at ESMO Gynecological Cancers
Corcept Therapeutics Incorporated disclosed efficacy and safety data from a subset analysis of the Phase 3 ROSELLA study, focusing on patients aged 65 years and older with platinum-resistant ovarian cancer (PROC). The data, presented by Lorusso et al. at the 2026 ESMO Gynecological Cancers Congress, examined the combination of relacorilant, Corcept's selective cortisol modulator, with nab-paclitaxel in this specific patient population.
The ROSELLA trial, also designated as GOG-3073, ENGOT-OV72, and APGOT-Ov10, represents a collaborative effort across multiple oncology research groups. Platinum-resistant ovarian cancer poses significant treatment challenges, particularly in older patients who may face additional comorbidities and tolerability concerns with conventional chemotherapy regimens.
Relacorilant Development Strategy
Relacorilant is designed to block the glucocorticoid receptor selectively, a mechanism Corcept has pursued to address cortisol-related tumor resistance. The company has positioned this asset as a potential differentiated therapy in oncology, building on its expertise in cortisol modulation that underpins its Cushing's syndrome franchise.
The age-specific analysis addresses a clinically relevant question, as ovarian cancer incidence increases with age and treatment decisions for elderly patients often require careful risk-benefit assessment.
Corporate Context
Corcept, valued at approximately $12 billion with shares closing at $114.49, is scheduled to report third-quarter 2026 results on November 4, according to MarginX data. The company operates in an evolving macroeconomic environment, with the Federal Reserve's September 16 meeting expected to include updated economic projections alongside its rate decision.
Recent insider activity shows Atabak Mokari, a company executive, exercised options for 24,167 shares and 15,833 shares in separate transactions, while selling 28,460 shares, per MarginX data. Such transactions are routine among executives managing equity compensation.
The presentation at ESMO provides additional clinical evidence for relacorilant's development program as Corcept seeks to expand beyond its existing commercial footprint in rare endocrine disorders into competitive oncology indications.
This article was generated by MarginX from public news on 2026-07-30. It is not investment advice.